Stocklytics Platform
Asset logo for symbol PRAX
Praxis Precision Medicines
PRAX57
$54.96arrow_drop_up1.64%$0.89
High Growth
Asset logo for symbol PRAX
PRAX57

$54.96

arrow_drop_up1.64%

Performance History

Chart placeholder
Key Stats
Open$55.59
Prev. Close$55.11
EPS-10.95
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range53.24
57.80
52 Week Range0.85
67.21
Ratios
EPS-10.95

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$857.46
Perf. (24h)
arrow_drop_up1.00%$8.56
Market Cap$764.35B
Price$565.33
Perf. (24h)
arrow_drop_up0.17%$0.98
Market Cap$519.41B
Price$154.69
Perf. (24h)
arrow_drop_down0.46%-$0.73
Market Cap$374.04B
Price$125.77
Perf. (24h)
arrow_drop_up1.22%$1.52
Market Cap$314.70B

About Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Marcio Souza M.B.A.
Headquarters
Boston
Employees
109
Exchange
NASDAQ
add Praxis Precision Medicines  to watchlist

Keep an eye on Praxis Precision Medicines

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Praxis Precision Medicines 's (PRAX) price per share?

The current price per share for Praxis Precision Medicines (PRAX) is $54.96. The stock has seen a price change of $0.89 recently, indicating a 1.65% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Praxis Precision Medicines (PRAX)?

For Praxis Precision Medicines (PRAX), the 52-week high is $67.21, which is 22.29% from the current price. The 52-week low is $0.85, the current price is 6.37K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Praxis Precision Medicines (PRAX) a growth stock?

Praxis Precision Medicines (PRAX) has shown an average price growth of 0.41% over the past three years. It has received a score of 100 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Praxis Precision Medicines as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Praxis Precision Medicines (PRAX) stock price performance year to date (YTD)?

As of the latest data, Praxis Precision Medicines (PRAX) has a year-to-date price change of 162.97%. Over the past month, the stock has experienced a price change of 37.02%. Over the last three months, the change has been 17.21%. Over the past six months, the figure is 46.87%.

help
Is Praxis Precision Medicines (PRAX) a profitable company?

Praxis Precision Medicines (PRAX) has a net income of -$123.28M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 82.35% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -9.72K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.45M, with a revenue growth rate of 67.14%, providing insight into the company's sales performance and growth. The gross profit is $2.02M. Operating income is noted at -$126.37M. Furthermore, the EBITDA is -$129.73M.

help
What is the market capitalization of Praxis Precision Medicines (PRAX)?

Praxis Precision Medicines (PRAX) has a market capitalization of $941.96M. The average daily trading volume is 355.54K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level